 |
     |
|
|
|
|
|
||
|
|
TARGETED MEDICINE | ||
|
Celera believes a better understanding of the genetic root cause of disease is the key to improved diagnosis and treatment of many complex chronic diseases. We have developed new tools and research methods to make the vital connection between genetic variation and disease. Our efforts are aimed at the prevention and earlier detection of disease, safer and more effective treatments, and reduced time and cost-to-market for new drugs. Together, we are seeking to translate our shared knowledge of genetics and genomics into breakthrough diagnostic and therapeutic products, an approach we call "Targeted Medicine."
Targeted Medicine integrates our understanding of genomics and its impact on disease throughout the discovery, development and commercialization of diagnostics and therapeutics. Large scale disease association studies on our diagnostics platform utilize genotyping, gene expression and bioinformatics platforms, and findings from the Applera Genomics Initiative, to identify genetic markers linked to the disease. A group of markers, which we call a “constellation,” can be configured into new molecular diagnostic tests intended to help physicians predict, characterize, monitor and select therapies for common, complex diseases. Some of these genetic markers may also be considered as potential therapeutic targets for new therapeutics. As we move forward, we intend to use this information to enable partners to stratify patient populations in clinical trial design. Patient stratification is intended to eliminate individuals from a trial who are less likely to respond to a drug, or more likely to experience adverse affects.
|
